LATOBACILLUS LACTIS
- Constipação crônica;
- Colite.
É recomendado o uso de 109 UFC/dia.
Podem ocorrer gases intestinais ou inchaço.
Armazenar em ambiente com temperatura entre 15 a 25o C.
Podem ocorrer gases intestinais ou inchaço.
Armazenar em ambiente com temperatura entre 15 a 25o C.
1. Jayasimhan S, et al. Efficacy of microbial cell preparation in improving chronic constipation: a randomized, double-blind, placebo-controlled trial; Clin Nutr; 2013 Dec;32; pg:928-34.
2. Fedorak RN, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group; Gastroenterology 119; pg:1473-82, 2000.
3. Ramasamy R, et al. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations; Vaccine 24; pg:3900-8, 2006
LATOBACILLUS LACTIS
- Constipação crônica;
- Colite.
É recomendado o uso de 109 UFC/dia.
Podem ocorrer gases intestinais ou inchaço.
Armazenar em ambiente com temperatura entre 15 a 25o C.
Podem ocorrer gases intestinais ou inchaço.
Armazenar em ambiente com temperatura entre 15 a 25o C.
1. Jayasimhan S, et al. Efficacy of microbial cell preparation in improving chronic constipation: a randomized, double-blind, placebo-controlled trial; Clin Nutr; 2013 Dec;32; pg:928-34.
2. Fedorak RN, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group; Gastroenterology 119; pg:1473-82, 2000.
3. Ramasamy R, et al. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations; Vaccine 24; pg:3900-8, 2006
LATOBACILLUS LACTIS
- Constipação crônica;
- Colite.
É recomendado o uso de 109 UFC/dia.
Podem ocorrer gases intestinais ou inchaço.
Armazenar em ambiente com temperatura entre 15 a 25o C.
1. Jayasimhan S, et al. Efficacy of microbial cell preparation in improving chronic constipation: a randomized, double-blind, placebo-controlled trial; Clin Nutr; 2013 Dec;32; pg:928-34.
2. Fedorak RN, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group; Gastroenterology 119; pg:1473-82, 2000.
3. Ramasamy R, et al. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations; Vaccine 24; pg:3900-8, 2006
